SIBUTRAMINA 15mg. Capsules.
$90.00 – $360.00
The Product it’s In Stock and Ready to Go Out, the Price Includes the Release of the Prescription, Duty-Free, Tax and all Fees, and We Also Send All Orders From a Safe Place, To Avoid Mail Lifters, Customs Hassle, and Shipping Issues, and We Always Use Special Courier Companies like FedEx and/or U.P.S. Via Two Days Air and/or Second Day Air, With No Signature Required, and We do Send Discrete Flat Envelope With no Medical or Pharmaceutical Tags, to Protect the Right of Privacy of Our Customers; We Also Have a Confidentiality Clause, and We Don’t Share Our Customers Information With Third Persons
This Product Belongs to the Opioid Narcotic Pain Medication Group, Classified by the F.D.A. On Schedule # II of Controlled Substances, for Exclusive use of Clinics & Hospitals; And We Offer These Top Quality Products From the Original Laboratories Approved by the F.D.A.
Ps. Buying Products From Other Unknown Countries and From All the Scam OnLine Pharmacies With No Health Regulations like Pakistan, India, China, Asian, or Central and South America, You Have the Risk to Get An Strong Infection or Get Poisoned by Not Regulated Suspicious Products and Fake Drugs, Mixed with Other Deadly Substances or Adulterants They Offer, Made in Clandestine Laboratories in the Worst Health Conditions and Environment Where the Products Can Be Contaminated, Because They are Fake Product, Weak Generics, Street Unknown Drugs, HomeMade or Counterfeit Because it’s Impossible For this Countries To Get the Original Presentations
Sibutramine Hydrochloride 15mg.
Meridia is indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet. Meridia is recommended for obese patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors (e.g., diabetes, dyslipidemia, controlled hypertension).
Below is a chart of Body Mass Index (BMI) based on various heights and weights.
BMI is calculated by taking the patient’s weight, in kg, and dividing by the patient’s height, in meters, squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters.
Each Meridia capsule contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin capsule [which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg capsules only); D&C Yellow No. 10 (5- and 15-mg capsules only), and other inactive ingredients].
Sibutramine produces its therapeutic effects by norepinephrine, serotonin and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines.
<strong>MERIDIA DOSAGE AND ADMINISTRATION</strong>
The recommended starting dose of Meridia is 10 mg administered once daily with or without food. If there is inadequate weight loss, the dose may be titrated after four weeks to a total of 15 mg once daily. The 5 mg dose should be reserved for patients who do not tolerate the 10 mg dose. Blood pressure and heart rate changes should be taken into account when making decisions regarding dose titration (see WARNINGS and PRECAUTIONS).
Doses above 15 mg daily are not recommended. In most of the clinical trials, Meridia was given in the morning.
Analysis of numerous variables has indicated that approximately 60% of patients who lose at least 4 pounds in the first 4 weeks of treatment with a given dose of Meridia in combination with a reduced-calorie diet lose at least 5% (placebo-subtracted) of their initial body weight by the end of 6 months to 1 year of treatment on that dose of Meridia. Conversely, approximately 80% of patients who do not lose at least 4 pounds in the first 4 weeks of treatment with a given dose of Meridia do not lose at least 5% (placebo-subtracted) of their initial body weight by the end of 6 months to 1 year of treatment on that dose. If a patient has not lost at least 4 pounds in the first 4 weeks of treatment, the physician should consider reevaluation of therapy which may include increasing the dose or discontinuation of Meridia.
The safety and effectiveness of Meridia, as demonstrated in double-blind, placebo-controlled trials, have not been determined beyond 2 years at this time.
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP controlled room temperature]. Protect capsules from heat and moisture. Dispense in a tight, light-resistant container as defined in USP.
30 capsules, 90 capsules, 120 capsules
Only logged in customers who have purchased this product may leave a review.